Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Vertex Pharmaceuticals (NQ: VRTX ) 495.26 +3.00 (+0.61%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Vertex Pharmaceuticals < Previous 1 2 3 4 5 6 Next > Vertex Reports Fourth Quarter and Full Year Financial 2022 Results February 07, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Is Biotech Immunocore About To Make A 25% Price Move? February 07, 2023 Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher. Via MarketBeat Topics ETFs Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7 January 17, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9 January 04, 2023 From Vertex Pharmaceuticals Incorporated Via Business Wire Harpoon Therapeutics Remains Volatile After Promising News December 14, 2022 Harpoon Therapeutics offers an example of biotech's volatility. The stock advanced as much as 191% intraday Monday before settling down to a gain of 22.61%. Via MarketBeat Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA December 12, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex and CRISPR Therapeutics to Present at the American Society of Hematology (ASH) Annual Meeting and Exposition December 10, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1) December 08, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report? November 11, 2022 Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel. Via MarketBeat Vertex to Participate in Upcoming Investor Conferences November 09, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex Announces Partnership with Basketball Hall-of-Famer Alonzo Mourning to Raise Awareness of APOL1-Mediated Kidney Disease (AMKD) November 04, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex to Present New Data on its Portfolio of Cystic Fibrosis Medicines at the 2022 North American Cystic Fibrosis Conference November 03, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex Reports Third Quarter 2022 Financial Results October 27, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex to Announce Third Quarter 2022 Financial Results on October 27 October 13, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex Advances Program Targeting Alpha-1 Antitrypsin Deficiency October 11, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex Shares Higher On Optimism About CRISPR Partnership October 05, 2022 Shares of Vertex Pharmaceuticals are moving higher on news that regulators gave the company the go-ahead to on the review process for gene-editing treatments. Via MarketBeat Exposures Product Safety Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022 September 27, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex Appoints Jonathan Biller as Chief Legal Officer September 08, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex Announces U.S. FDA Approval for ORKAMBI® (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 12 to <24 months September 02, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Obesity And Back Pain: BioRestorative Therapies Inc. Is Working To Address 2 Common Ailments That Plague Americans with a Major Near Term Data Catalyst September 01, 2022 In 2016, Americans spent roughly $380 billion on lower back and neck pain. In the same year, medical costs for adult obesity in the United States were $260.6 billion. That’s why BioRestorative... Via TheNewswire.com Vertex to Participate in the Wells Fargo Healthcare Conference on Friday, September 9 August 31, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex Reports Second Quarter 2022 Financial Results August 04, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex Advances VX-548 in Acute and Neuropathic Pain July 22, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex to Announce Second Quarter 2022 Financial Results on August 4 July 18, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes July 11, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes July 05, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress June 11, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference June 10, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex to Participate in the Goldman Sachs 43rd Annual Healthcare Conference on June 15 June 08, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA June 08, 2022 From Vertex Pharmaceuticals Incorporated Via Business Wire < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.